XXXX and @entity792 : more than a fortuitous association?

@entity1 @entity644 @entity229 @entity1011 @entity631 @entity792
@entity631 ( @entity631 ) results from genetic or acquired dysregulation of the alternative complement pathway. A subset of @entity1 may have clinical and biochemical characteristics compatible with an @entity792 . We studied a cohort of 85 @entity1 with confirmed @entity631 (2007-2014), of which ten @entity1 (3 male, 7 female; mean age 38.5  years) had an associated @entity792 . All @entity1 had abnormal ANA titers, 6 also had positive ds-DNA titers. At the time of presentation with @entity631 , all 7 female @entity1 had autoimmune-related presentations. Of the 3 male @entity1 , only 1 @entity1 had autoimmune-related presentations. Kidney biopsy showed predominantly mesangial proliferative or @entity631 . In 5 @entity1 , the alternative pathway was evaluated. All had allele variants/polymorphisms associated with @entity631 . One @entity1 was also positive for C3Nefs. Treatment varied form conservative management to the use of @entity229 alone or with cytotoxic therapy. Mean serum @entity1011 decreased from 2.0 to 1.4  mg/dL while @entity644 decreased from 2300 to 994  mg/24  h in 8 @entity1 with follow-up. The study highlights the association between @entity631 and @entity792 , particularly in female @entity1 . The study suggests that an autoimmune milieu may act as a trigger for the development of @entity631 in genetically susceptible @entity1 . Short-term prognosis of @entity631 associated with @entity792 appears excellent.
